福利导航

We are economists and thinkers from a range of disciplines who challenge conventional wisdom and advance ideas to better serve society.

Research

We develop research that challenges economic orthodoxy and serves society.

Articles

Commentary, analysis, interviews, and research summaries by INET-affiliated writers.

Video

Interviews, presentations and video series with provocative economic thinkers, public figures and students.

福利导航s and Beyond with Rob Johnson, a podcast featuring interviews with some of the world’s most important thinkers, artists, and activists about the pressing issues of our time. The podcast is also available on all major podcasting platforms, such as Apple, Spotify, Google, and Podbean.

Education

Video series and courses for students and educators interested in exploring new economic thinking.

Events

To foster new economic thinking, we host convenings that gather together a diverse community of thinkers from different fields, countries, and schools of thought.

YSI

Through the Young Scholars Initiative (YSI), INET provides support to students, young professionals, or others who embrace new and critical ways of thinking about the economy. YSI fosters conversation among those who wish to engage with new economic thinking and connects young scholars to the Institute鈥檚 vast network of economists.

Topics

Browse all INET content organized by topic

Talha Syed

Lecturer, UC Berkeley Law

Talha Syed teaches Intellectual Property, Antitrust, Torts, and Legal Theory at UC Berkeley Law. His research focuses on these fields, as well as theories of distributive justice, all from a “law and political economy” (LPE) perspective. He has most recently published “Does Pharma Need Patents?” in the Yale Law Journal and is working on the of a distinctive LPE approach to legal and social theory. In that vein, he has recently participated in a series of debates and symposia on this front, including and .

By this expert

Rethinking Pharmaceutical Innovation Policy

Article By Talha Syed | May 19, 2025

Misaligned incentives account for many of the most troubling features of the pharmaceutical industry鈥檚 present practices and performance.